This suggests that it is the relative levels of α-synuclein pathology between ACC and PCC that relate to the metabolic differences that give the CIS—high levels of α-synuclein in ACC leading to lower metabolism relative to lower levels of α-synuclein pathology in the PCC and preserved metabolism. This evidence concerns the gene SNCA and in situ carcinoma.